康哲药业(00867)：自主研发创新药INHBE小核酸药物CMS-D008获得超重或肥胖适应症药物临床试验批准通知书

智通财经03-04

智通财经APP讯，康哲药业(00867)发布公告，本集团自主研发的创新药INHBE小核酸药物CMS-D008注射液(CMS-D008)于2026年3月4日获得中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书。NMPA同意开展CMS-D008注射液用于超重或肥胖的临床试验。CMS-D008是一款皮下注射的siRNA药物，靶向抑制肝脏的抑制素亚基βE(INHBE)基因表达，下调INHBE...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2616253165?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-04 18:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616253165","market":"us","top_or_hot":-1,"title":"康哲药业(00867)：自主研发创新药INHBE小核酸药物CMS-D008获得超重或肥胖适应症药物临床试验批准通知书","media":"智通财经","content":"<div>\n<p>智通财经APP讯，康哲药业(00867)发布公告，本集团自主研发的创新药INHBE小核酸药物CMS-D008注射液(CMS-D008)于2026年3月4日获得中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书。NMPA同意开展CMS-D008注射液用于超重或肥胖的临床试验。CMS-D008是一款皮下注射的siRNA药物，靶向抑制肝脏的抑制素亚基βE(INHBE)基因表达，下调INHBE...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1410029.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康哲药业(00867)：自主研发创新药INHBE小核酸药物CMS-D008获得超重或肥胖适应症药物临床试验批准通知书</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康哲药业(00867)：自主研发创新药INHBE小核酸药物CMS-D008获得超重或肥胖适应症药物临床试验批准通知书\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-04 18:58 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1410029.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，康哲药业(00867)发布公告，本集团自主研发的创新药INHBE小核酸药物CMS-D008注射液(CMS-D008)于2026年3月4日获得中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书。NMPA同意开展CMS-D008注射液用于超重或肥胖的临床试验。CMS-D008是一款皮下注射的siRNA药物，靶向抑制肝脏的抑制素亚基βE(INHBE)基因表达，下调INHBE...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1410029.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1410029.html","article_id":"2616253165","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616253165","pubTimestamp":1772621908,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，康哲药业 发布公告，本集团自主研发的创新药INHBE小核酸药物CMS-D008注射液于2026年3月4日获得中国国家药品监督管理局签发的药物临床试验批准通知书。NMPA同意开展CMS-D008注射液用于超重或肥胖的临床试验。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","BK1593":"医美概念股","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","BK4585":"ETF&股票定投概念","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC","SG9999015978.USD":"利安颠覆性创新基金A","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","LU2500361329.USD":"NORDEA 1 GLOBAL SUSTAINABLE LISTED REAL ASSETS \"B\" (USD) ACC","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","CMS":"CMS能源","LU2637428348.USD":"NORDEA 1 GLOBAL SUSTAINABLE LISTED REAL ASSETS \"MP\" (USD) INC","BK4588":"碎股","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","06978":"永泰生物-B","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","BK4208":"复合型公用事业","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","00867":"康哲药业","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","BK1574":"生物医药B类股","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","BK1161":"生物科技","BK1191":"制药","LU2346227817.USD":"BGF SUSTAINABLE GLOBAL INFRASTRUCTURE \"A2\" (USD) ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC"},"translate_title":"CMS Pharmaceutical (00867): The independently developed innovative drug INHBE small nucleic acid drug CMS-D008 obtained the approval notice for clinical trials of overweight or obesity indications","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"00867":1.5,"CMS":1.5,"06978":1.5},"content_text":"智通财经APP讯，康哲药业(00867)发布公告，本集团自主研发的创新药INHBE小核酸药物CMS-D008注射液(CMS-D008)于2026年3月4日获得中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书。NMPA同意开展CMS-D008注射液用于超重或肥胖的临床试验。CMS-D008是一款皮下注射的siRNA药物，靶向抑制肝脏的抑制素亚基βE(INHBE)基因表达，下调INHBE编码蛋白激活素E(ActivinE)水平，从而降低脂肪代谢通路Activin E-ALK7的活化，有效减少脂质堆积。临床前研究提示CMS-D008高效持续抑制INHBE 表达，肥胖动物模型中，在不影响肌肉的情况下，获得明显的减重减脂效果，安全性良好，显示减脂不减肌，长期高质量减重的良好前景，未来可开发治疗超重/肥胖，腹型肥胖以及相关代谢性疾病。超重或肥胖是一种脂肪组织过度积累或分布、功能异常的慢性、进行性、复发性疾病。根据《2025年世界肥胖报告》，预测到2030年，全球超重和肥胖成年人的比例会上升到50%，将有近30亿成年人受到高体重指数(BMI)的影响，我国成人超重/肥胖人数将达到5.15亿。现有的GLP-1RA类药物显示了很好的减重效果，该类药物主要通过作用于中枢神经系统抑制食欲，延缓胃排空来降低体重，而INHBE不同于GLP-1类药物的作用机制，是从全基因组关联分析筛选获得，INHBE功能丧失的人群拥有良好的体脂分布和有利的代谢特征，靶向抑制INHBE可以从基因水平精准减少内脏脂肪，改善代谢状态，更有利于长期体重管理。CMS-D008 将与正处于临床开发阶段的自研创新药CMS-D005形成协同，CMS-D008通过精准抑制INHBE基因表达，减脂不减肌;而CMS-D005作为GLP-1R/GCGR双重激动剂，可在减重同时，强效降低肝脏脂肪，二者协同实现高效的减重获益与长期的成果维持，共同增强本集团在肥胖/代谢治疗领域的研发实力与产品竞争力，并依托本集团在心血管代谢疾病领域成熟的网络资源，加速药物的研发与商业化进程，为患者提供更全面、创新的治疗方案。本集团正积极准备开展相关临床试验工作，力争该产品尽快上市。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616253165","isCrawlerRequest":true}